Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma

Cancer

Volumn 117, Issue 5, 2011, Pages 1010-1018

  Zinzani, Pier Luigi ^a   Gandolfi, Letizia ^a   Broccoli, Alessandro ^a   Argnani, Lisa ^a   Fanti, Stefano ^a   Pellegrini, Cinzia ^a   Stefoni, Vittorio ^a   Derenzini, Enrico ^a   Quirini, Federica ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Aggressive non Hodgkin lymphoma; Chemo immunotherapy; Midtreatment PET; Primary mediastinal large B cell lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FOLINIC ACID; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; EVENT FREE SURVIVAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ALGORITHM; CANCER INVASION; CANCER STAGING; DRUG ADMINISTRATION; EVALUATION; METHODOLOGY; MIDDLE AGED; MONITORING; MORTALITY; NONHODGKIN LYMPHOMA; PATHOLOGY; SCINTISCANNING; SURVIVAL; TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEUCOVORIN; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; MONITORING, PHYSIOLOGIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 79952030722     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25579     Document Type: Article

References (43)

1. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50:21S-30S.
2. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma. 2009;50:1931-1936.
3. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
4. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J ClinOncol. 2009;27:1781-1787.
5. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
6. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381. (Pubitemid 41129604)
7. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523. (Pubitemid 41222425)
8. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma - comparison with CT. Leuk Lymphoma. 2000;39:543-553. (Pubitemid 32162393)
9. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527-533.
10. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503-507.
11. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632. (Pubitemid 47572710)
12. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
13. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
14. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025-3030. (Pubitemid 30644128)
15. Gisselbrecht C, Lepage E, Molina T, et al. Groupe d'Etude des Lymphomes de l'Adulte. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472-2479. (Pubitemid 34525732)
16. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262. (Pubitemid 46606401)
17. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol. 2002;20:4413-4419.
18. Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1995;332:1045-1051.
19. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
20. Rosenwald A, Wright G, Chan WC, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947. (Pubitemid 34651353)
21. Lenz G, Wright G, Dave SS, et al. Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
22. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1837. (Pubitemid 38917249)
23. Zinzani PL, Broccoli A, Stefoni V, et al. Immunophenotype and intermediate-high IPI score as prognostic factors for upfront intensification therapy in diffuse large B-cell lymphoma patients [published online ahead of print August 24, 2010]. Cancer. doi: 10.1002/cncr.25307.
24. Cheson B. The case against heavy PETing. J Clin Oncol. 2009;27:1742-1743.
25. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours. Pathology and Genetics: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
26. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
27. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602. (Pubitemid 15120476)
28. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999;94:33-38. (Pubitemid 29300131)
29. Fina M, Tani M, Stefoni V, et al. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leuk Lymphoma. 2007;48:2167-2171. (Pubitemid 350091058)
30. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma. 2000;39:543-553. (Pubitemid 32162393)
31. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group [erratum appears in J Clin Oncol. 2000;18:2351]. J Clin Oncol. 1999;17:1244-1253.
32. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
33. Kaplan ES, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;58:457-481.
34. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin's disease. Cancer. 2006;107:2678-2687. (Pubitemid 44845624)
35. Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775-777.
36. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1824-1833.
37. Han HS, Escalon MP, Hsiao B, et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009;20:309-318.
38. Weber WA. 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative? J Nucl Med. 2007;48:1580-1582.
39. Safar V, Dupuis J, Jardin F, et al. Early 18fluorodeoxyglucose PET scan as a prognostic tool in diffuse large B-cell lymphoma patients treated with an anthracycline-based chemotherapy plus rituximab. Blood. 2009;114.
40. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLCL) Blood. 2008;112.
41. Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-positron emission tomography/computed tomography (PET) failed to predict different outcome in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab-CHOP. Blood. 2009;114:99S.
42. Micallef IN, Maurer MJ, Witzig TE, et al. PET scan results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2009;114:.
43. Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15:242-248.